<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03110458</url>
  </required_header>
  <id_info>
    <org_study_id>SENSORION</org_study_id>
    <nct_id>NCT03110458</nct_id>
  </id_info>
  <brief_title>Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy</brief_title>
  <acronym>SENS 111-201</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 2 Dose Regimens of Orally Administered SENS-111 (100 mg and 200 mg) Given During 4 Days in Patients Suffering From Acute Unilateral Vestibulopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sensorion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sensorion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and
      safety of 2 dose-regimens of orally administered SENS-111 (100mg and 200mg) given during 4
      days in patients suffering from Acute Unilateral Vestibulopathy (AUV)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standing vertigo intensity</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>By Visual analogue scale (VI-VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Worst spontaneous vertigo intensity</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>By Visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proprioception</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>By the score of the Romberg tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vestibular spontaneous nystagmus</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>By oculography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea severity</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>By Visual Analogue Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>By the incidence of adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">207</enrollment>
  <condition>Acute Unilateral Vestibulopathy (AUV)</condition>
  <arm_group>
    <arm_group_label>SENS-111 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SENS-111 100mg: 2ODT (1 ODT SENS-111 and 1 ODT placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SENS-111 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SENS-111 200mg: 2 ODTs SENS-111</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: 2 placebo ODTs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SENS-111 100mg</intervention_name>
    <description>2 ODT (1 ODT SENS-111 and 1 ODT placebo)</description>
    <arm_group_label>SENS-111 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SENS-111 200mg</intervention_name>
    <description>2 ODT (2 ODT SENS-111)</description>
    <arm_group_label>SENS-111 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>2 ODT (2 ODT placebo)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria includes, but is not limited to:

        * Subject has a diagnosis of definite Acute Unilateral Vestibulopathy

        Exclusion criteria includes, but is not limited to:

          -  Acute continuous vertigo lasting more than 72 hours prior to randomization

          -  History of acute or chronic vestibular diseases

          -  History of prior acute central vestibular lesion

          -  Acute or chronic disease of middle ear
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael STRUPP, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MÃ©lina BLAIRVACQ, CRA</last_name>
    <phone>+33 4 34 08 71 17</phone>
    <email>melina.blairvacq@sensorion-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>STRUPP</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute unilateral vestibulopathy, AUV</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

